INITIAL RESULTS OF THE TAXANE REGIMEN COMBINED WITH TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE RECURRENT OR METASTASIS BREAST CANCER

Hoài Bùi Thị Thu, Đức Lê Thanh

Main Article Content

Abstract

Aims: Assessment of treatment response and progression-free survival in Her2-positive metastatic or recurrent breast cancer, utilizing a combination of taxane, trastuzumab, and pertuzumab. Research subject: Thirty patients diagnosed with metastatic recurrent breast cancer were treated with a taxane combined with trastuzumab and pertuzumab at K Hospital from 2018 to 2024. Patients and Methods: Descriptive research. Results: The overall response rate for the treatment regimen was 93.4%. This included a complete response rate of 16.7% and a partial response rate of 76.7%. The mean progression-free survival time was 27.0 ± 4.0 months, while the median was 24.4 ± 6.5 months (the shortest was 2 months and the longest was 50.8 months). Additionally, no significant associations were found between progression-free survival time and factors such as age group, hormone receptor status, visceral metastasis status, prior trastuzumab treatment history, or type of taxane used. Conclusion: Taxane combined with trastuzumab and pertuzumab is a highly effective first-line treatment regimen for patients with Her2-positive recurrent or metastatic breast cancer.

Article Details

References

1. Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209–249.
2. Wolff A.C., Hammond M.E.H., Schwartz J.N. và cộng sự. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131(1), 18–43.
3. Scheuer W., Friess T., Burtscher H. và cộng sự. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res, 69(24), 9330–9336.
4. Baselga J., Cortés J., Kim S.-B. và cộng sự. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366(2), 109–119.
5. Bachelot T., Ciruelos E., Schneeweiss A. và cộng sự. (2019). Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol Off J Eur Soc Med Oncol, 30(5), 766–773.
6. Takahashi M., Ohtani S., Nagai S.E. và cộng sự. (2021). The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. Breast Cancer Res Treat, 185(1), 125–134.
7. De Placido S., Giuliano M., Schettini F. và cộng sự. (2018). Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast Edinb Scotl, 38, 86–91.
8. Gamucci T., Pizzuti L., Natoli C. và cộng sự. (2019). A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Cancer Biol Ther, 20(2), 192–200.